Strategic partnerships Andelyn Biosciences is actively expanding its client portfolio with collaborations and scale-up manufacturing for gene therapies, including recent engagements with Genprex and Queen's University. This signals strong outbound opportunities in oncology and neuromuscular/gene therapy spaces where partners seek scalable GMP production.

Capability expansion The launch of a lentiviral vector manufacturing platform and ongoing development of AAV9-GM2 programs indicate capabilities to support diverse vector platforms and large-scale cell and gene therapy programs, creating cross-sell opportunities for vector development, process validation, and clinical-to-commercial manufacturing.

Geographic/market reach Located in Columbus, Ohio with a substantial 180,000-square-foot facility capable of clinical and commercial scale, Andelyn is positioned to attract mid-to-large scale programs in the U.S. market, offering near-term capacity for growing client demand and faster time-to-scale.

End-to-end services With viral vector process and analytical development, GMP manufacturing up to 2000 L, plasmid production, advanced quality systems, and integrated supply chain, Andelyn provides a comprehensive CDMO solution that reduces vendor fragmentation for sponsors pursuing streamlined development-to-commercialization pathways.

Financials & growth signal Revenue in the reported range suggests a robust mid-market standing and healthy demand for gene therapy manufacturing services, complemented by ongoing client wins and multi-program engagements that indicate potential budget-aligned selling opportunities with growth-stage biotechs and academic partners.